Teva MS Success Helps Stock In Down Month: Biogen, Chiron Tumble
Executive Summary
Teva's smooth performance in the multiple sclerosis market is shoring up the company in a difficult environment for biopharmaceutical stocks.
You may also be interested in...
Teva/BTG Tev-Tropin
Teva/Bio-Technology General Corp.'s human growth hormone Tev-Tropin will be introduced "at the earliest opportunity" following U.S. appellate court decision to vacate June 2002 preliminary injunction against U.S. marketing of the product, BTG says. The injunction was requested by Novo. The company's process patent case arose out of previous process patent litigation between BTG and Genentech, which was resolved when BTG received FDA approval to change its manufacturing process (1"The Pink Sheet" May 8, 2000, p. 22). Novo claimed BTG's manufacturing change violated Novo patents. Teva holds marketing rights to Tev-Tropin and has ultimate decision on a launch date, BTG says...
Teva/BTG Tev-Tropin
Teva/Bio-Technology General Corp.'s human growth hormone Tev-Tropin will be introduced "at the earliest opportunity" following U.S. appellate court decision to vacate June 2002 preliminary injunction against U.S. marketing of the product, BTG says. The injunction was requested by Novo. The company's process patent case arose out of previous process patent litigation between BTG and Genentech, which was resolved when BTG received FDA approval to change its manufacturing process (1"The Pink Sheet" May 8, 2000, p. 22). Novo claimed BTG's manufacturing change violated Novo patents. Teva holds marketing rights to Tev-Tropin and has ultimate decision on a launch date, BTG says...
Teva Copaxone Nears U.K. Approval, But NICE To Refuse MS Drug Payment
Teva is expecting U.K. licensure of its multiple sclerosis drug Copaxone (glatiramer) in July for reduction in frequency of relapse in relapsing/remitting MS, the company indicated.